ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Net income

SanBio Company Limited (4592)

Market cap
¥159.8B
P/E ratio
-28.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Jan 31, 2026-3,843+33.29%
Jan 31, 2025-2,883+9.02%
Jan 31, 2024-2,644-52.44%
Jan 31, 2023-5,560+18.85%
Jan 31, 2022-4,678+38.16%
Jan 31, 2021-3,386-34.35%
Jan 31, 2020-5,158+76.60%
Jan 31, 2019-2,921-25.88%
Jan 31, 2018-3,940+114.70%
Jan 31, 2017-1,835+85.68%
Jan 31, 2016-988-156.93%
Jan 31, 20151,736-394.55%
Jan 31, 2014-589

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat